Viewing Study NCT05846750


Ignite Creation Date: 2025-12-24 @ 4:51 PM
Ignite Modification Date: 2026-04-13 @ 8:34 PM
Study NCT ID: NCT05846750
Status: RECRUITING
Last Update Posted: 2023-07-19
First Post: 2023-04-27
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module